Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Pauliina Molander, Martti Färkkilä, Helena Kemppainen, Timo Blomster, Airi Jussila, Harri Mustonen & Taina Sipponen. (2017) Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 52:3, pages 284-290.
Read now
Read now
Jon Florholmen. (2015) Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 50:1, pages 43-52.
Read now
Read now
Sonia Michail, Gilberto Bultron & R William DePaolo. (2013) Genetic variants associated with Crohn’s disease. The Application of Clinical Genetics 6, pages 25-32.
Read now
Read now
Articles from other publishers (38)
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollón, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik S Ding, Gabriele Dragoni, Federica Furfaro, Patrick F van Rheenen, Maria Chaparro, Javier P Gisbert, Edouard Louis & Konstantinos Papamichail. (2023) ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease. Journal of Crohn's and Colitis 17:7, pages 1031-1045.
Crossref
Crossref
Kay-Martin Johnsen, Jon Florholmen, Øystein K. Moe, Mona Gundersen, Julia Beilfuss, Hege Kileng, Sveinung W. Sørbye & Rasmus Goll. (2022) Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study. BMC Gastroenterology 22:1.
Crossref
Crossref
Sebastiaan ten Bokkel Huinink, Djuna C. de Jong, Daan Nieboer, Doranne Thomassen, Ewout W. Steyerberg, Marcel G.W. Dijkgraaf, Alexander G.L. Bodelier, Rachel L. West, Tessa E.H. Römkens, Frank Hoentjen, Rosalie C. Mallant, Bas A.C. van Tuyl, Wout G.N. Mares, Frank H.J. Wolfhagen, Gerard Dijkstra, Jurriën G.P. Reijnders, Nanne K. de Boer, Adriaan C.I.T.L. Tan, Petra G.A. van Boeckel, Greetje J. Tack, Dirk P. van Asseldonk, Geert R.A.M. D’Haens, C Janneke van der Woude, Marjolijn Duijvestein & Annemarie C de Vries. (2022) Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn’s disease. European Journal of Gastroenterology & Hepatology 34:10, pages 983-992.
Crossref
Crossref
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D’Haens, Annemarie C. de Vries, Annemarie C. de Vries, Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Jasmijn A.M. Sleutjes, Marjolijn Duijvestein, Geert R. D’Haens, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, José M. García-Ortiz, Robert Downey, Alenka J. Brooks, Peter J. Hamlin, Shaji Sebastian, Alan J. Lobo, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Levinus (Leo) A. Dieleman, Xavier Roblin, Shomron Ben-Horin, Klaudia Farkas, Jakob B. Seidelin, Casper Steenholdt & Steven Bots. (2022) Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology 20:8, pages 1671-1686.e16.
Crossref
Crossref
Guanglin Cui, Jon Florholmen & Rasmus Goll. (2022) Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?. Frontiers in Immunology 13.
Crossref
Crossref
Peter Bossuyt, Lieven Pouillon, Sophie Claeys, Soetkin D’Haens, Eveline Hoefkens, Beatrijs Strubbe, Denis Marichal & Harald Peeters. (2022) Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial. Journal of Crohn's and Colitis 16:2, pages 199-206.
Crossref
Crossref
Joseph Meredith, Paul Henderson, David C. Wilson, Johan Van Limbergen, Eytan Wine & Richard K. Russell. (2021) Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease—An International Survey of Practice. Journal of Pediatric Gastroenterology & Nutrition 73:1, pages 54-60.
Crossref
Crossref
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll & Jon Florholmen. (2021) Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. eBioMedicine 66, pages 103329.
Crossref
Crossref
Jon R. Florholmen, Kay-Martin Johnsen, Renate Meyer, Trine Olsen, Øystein K. Moe, Petter Tandberg, Mona D. Gundersen, Jan-Magnus Kvamme, Knut Johnsen, Terje Løitegård, Gabriele Raschpichler, Cecilia Vold, Sveinung W. Sørbye & Rasmus Goll. (2020) Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. BMC Gastroenterology 20:1.
Crossref
Crossref
Bing Zhang, Alakh Gulati, Omeed Alipour & Ling Shao. (2020) Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 14:10, pages 1413-1423.
Crossref
Crossref
Bahez Gareb, Antonius T. Otten, Henderik W. Frijlink, Gerard Dijkstra & Jos G. W. Kosterink. (2020) Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 12:6, pages 539.
Crossref
Crossref
Guoqing Hou & Shrinivas Bishu. (2020) Th17 Cells in Inflammatory Bowel Disease: An Update for the Clinician. Inflammatory Bowel Diseases 26:5, pages 653-661.
Crossref
Crossref
Shrinivas Bishu, Mohammed El Zaatari, Atsushi Hayashi, Guoqing Hou, Nicole Bowers, Jami Kinnucan, Beth Manoogian, Michelle Muza-Moons, Min Zhang, Helmut Grasberger, Charlie Bourque, Weiping Zou, Peter D R Higgins, Jason R Spence, Ryan W Stidham, Nobuhiko Kamada & John Y Kao. (2019) CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn’s Disease. Journal of Crohn's and Colitis 13:7, pages 905-915.
Crossref
Crossref
Dario Sorrentino, Vu Q. Nguyen & Maithili V. Chitnavis. (2019) Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 8:6, pages 548.
Crossref
Crossref
Gregor Novak, Toer Stevens, Tanja Van Viegen, Peter Bossuyt, Borut Štabuc, Jenny Jeyarajah, Guangyong Zou, Ingrid C. Gaemers, Trevor D. McKee, Fred Fu, Lisa M. Shackelton, Reena Khanna, Gijs R. van den Brink, William J. Sandborn, Brian G. Feagan, Rish K. Pai, Vipul Jairath, Niels Vande Casteele & Geert D’Haens. (2019) Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease. Alimentary Pharmacology & Therapeutics 49:11, pages 1401-1409.
Crossref
Crossref
Olga Maria Nardone, Rosanna Cannatelli, Davide Zardo, Subrata Ghosh & Iacucci Marietta. (2019) Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?. Therapeutic Advances in Gastroenterology 12, pages 175628481986301.
Crossref
Crossref
Catarina Frias Gomes, Jean-Frédéric Colombel & Joana Torres. (2018) De-escalation of Therapy in Inflammatory Bowel Disease. Current Gastroenterology Reports 20:8.
Crossref
Crossref
Ray K Boyapati, Joana Torres, Carolina Palmela, Claire E Parker, Orli M Silverberg, Sonam D Upadhyaya, Tran M Nguyen & Jean-Frédéric Colombel. (2018) Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database of Systematic Reviews 2018:5.
Crossref
Crossref
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska & Edouard Louis. (2018) European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:1, pages 17-31.
Crossref
Crossref
Shomron Ben-Horin, Ren Mao, Yun Qiu & Minhu Chen. (2018) Discontinuation of Biological Treatments in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 52:1, pages 6-12.
Crossref
Crossref
Hang Hock Shim & Cynthia H. Seow. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
141
162
.
Hadar Reichman, Italy Moshkovits, Michal Itan, Metsada Pasmanik-Chor, Thomas Vogl, Johannes Roth & Ariel Munitz. (2017) Transcriptome profiling of mouse colonic eosinophils reveals a key role for eosinophils in the induction of s100a8 and s100a9 in mucosal healing. Scientific Reports 7:1.
Crossref
Crossref
Wei-Chen LinJen-Wei ChouHsu-Heng YenWen-Hung HsuHung-Hsin LinJen-Kou LinChiao-Hsiung ChuangTien-Yu HuangHorng-Yuan WangShu-Chen WeiJau-Min Wong. (2017) Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study. Intestinal Research 15:4, pages 487.
Crossref
Crossref
Kay-Martin Johnsen, Rasmus Goll, Vegard Hansen, Trine Olsen, Renathe Rismo, Richard Heitmann, Mona D. Gundersen, Jan M. Kvamme, Eyvind J. Paulssen, Hege Kileng, Knut Johnsen & Jon Florholmen. (2017) Repeated intensified infliximab induction – results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. European Journal of Gastroenterology & Hepatology 29:1, pages 98-104.
Crossref
Crossref
Jean-Frederic Colombel, Neeraj Narula & Laurent Peyrin-Biroulet. (2017) Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 152:2, pages 351-361.e5.
Crossref
Crossref
Mona Dixon Gundersen, Rasmus Goll, Johanna Hol, Trine Olsen, Renathe Rismo, Sveinung W. Sørbye, Olav Sundnes, Guttorm Haraldsen & Jon Florholmen. (2016) Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis. Scientific Reports 6:1.
Crossref
Crossref
Aranzazu Jauregui Amezaga & Gert Van Assche. (2016) Practical Approaches to “Top–Down” Therapies for Crohn’s Disease. Current Gastroenterology Reports 18:7.
Crossref
Crossref
Javier P Gisbert, Alicia C Marín & María Chaparro. (2016) The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 111:5, pages 632-647.
Crossref
Crossref
Joana Torres, Marília Cravo & Jean-Frédéric Colombel. (2016) Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Portuguese Journal of Gastroenterology 23:3, pages 153-161.
Crossref
Crossref
Trine Olsen, Renathe Rismo, Mona Dixon Gundersen, Eyvind J. Paulssen, Knut Johnsen, Jan-Magnus Kvamme, Rasmus Goll & Jon Florholmen. (2016) Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis. Cytokine 79, pages 90-95.
Crossref
Crossref
Stephanie M. Slevin & Laurence J. Egan. (2015) New Insights into the Mechanisms of Action of Anti–Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 21:12, pages 2909-2920.
Crossref
Crossref
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel & Jack Satsangi. (2015) Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 149:7, pages 1716-1730.
Crossref
Crossref
Aping Yuan, Hang Yang, Haili Qi, Jing Cui, Wei Hua, Can Li, Zhigang Pang, Wei Zheng & Guanglin Cui. (2015) IL-9 antibody injection suppresses the inflammation in colitis mice. Biochemical and Biophysical Research Communications 468:4, pages 921-926.
Crossref
Crossref
J. P. Gisbert, A. C. Marín & M. Chaparro. (2015)
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐
TNF
therapy
. Alimentary Pharmacology & Therapeutics 42:4, pages 391-405.
Crossref
Crossref
Raquel Franco Leal, Núria Planell, Radhika Kajekar, Juan J Lozano, Ingrid Ordás, Isabella Dotti, Miriam Esteller, M Carme Masamunt, Harsukh Parmar, Elena Ricart, Julián Panés & Azucena Salas. (2015) Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy. Gut 64:2, pages 233-242.
Crossref
Crossref
Konstantinos Papamichael. (2015) Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World Journal of Gastroenterology 21:16, pages 4773.
Crossref
Crossref
Konstantinos H Katsanos & Konstantinos A Papadakis. (2014) Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 15:16, pages 2049-2062.
Crossref
Crossref
Dario Sorrentino, Peter Nash, Monica Viladomiu, Raquel Hontecillas & Josep Bassaganya-Riera. (2014) Stopping Anti-TNF Agents in Patients with Crohnʼs Disease in Remission. Inflammatory Bowel Diseases 20:4, pages 757-766.
Crossref
Crossref